{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:10:38Z","timestamp":1778551838164,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["FPR3757"],"award-info":[{"award-number":["FPR3757"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["61003835"],"award-info":[{"award-number":["61003835"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023961","name":"Centro de Investigaci\u00f3n Biotecnol\u00f3gica en Red de Enfermedades Infecciosas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023961","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007680","name":"Universidad P\u00fablica de Navarra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005731","name":"Juntendo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ijantimicag.2023.106836","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T21:34:52Z","timestamp":1683322492000},"page":"106836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia"],"prefix":"10.1016","volume":"62","author":[{"given":"Patricia","family":"Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-3269","authenticated-orcid":false,"given":"Miriam","family":"Moscoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Carmen","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-7003","authenticated-orcid":false,"given":"V\u00edctor","family":"Fuentes-Valverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-3332","authenticated-orcid":false,"given":"Astrid","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germ\u00e1n","family":"Bou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106836_bib0001","series-title":"Antimicrobial resistance surveillance in Europe 2022 \u20132020 data","year":"2022"},{"issue":"Suppl 4","key":"10.1016\/j.ijantimicag.2023.106836_bib0002","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106836_bib0003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2023.106836_bib0004","article-title":"Limitations of vancomycin in the management of resistant staphylococcal infections","volume":"45","author":"Kollef","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106836_bib0005","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.50.4.1581-1585.2006","article-title":"Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin","volume":"50","author":"Sakoulas","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106836_bib0006","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2011.01.017","article-title":"Ceftaroline: a comprehensive update","volume":"37","author":"Kaushik","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106836_bib0007","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/jcpt.12743","article-title":"Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Lewis","year":"2018","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106836_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106836_bib0009","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/antibiotics8010030","article-title":"A mini-review on ceftaroline in bacteremia patients with methicillin-resistant Staphylococcus aureus (MRSA) Infections","volume":"8","author":"Lounsbury","year":"2019","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106836_bib0010","doi-asserted-by":"crossref","first-page":"ofab606","DOI":"10.1093\/ofid\/ofab606","article-title":"Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection","volume":"9","author":"Zasowski","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106836_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/10600280221082326","article-title":"Ceftaroline: systematic review of clinical uses and emerging drug resistance","author":"Abate","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106836_bib0012","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1128\/AAC.00372-11","article-title":"Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijantimicag.2023.106836_bib0013","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1128\/AAC.01078-12","article-title":"Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model","volume":"56","author":"Bhalodi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ijantimicag.2023.106836_bib0014","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1128\/AAC.03652-14","article-title":"Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter","volume":"58","author":"So","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106836_bib0015","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1128\/AAC.01242-06","article-title":"In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model","volume":"51","author":"Jacqueline","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106836_bib0016","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106836_bib0017","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106836_bib0018","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkl222","article-title":"Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus","volume":"58","author":"Reyes","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106836_bib0019","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/jac\/dkm417","article-title":"Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus","volume":"61","author":"Hegde","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.ijantimicag.2023.106836_bib0020","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1128\/AAC.00062-10","article-title":"Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model","volume":"54","author":"Crandon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106836_bib0021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106836_bib0022","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.01046-07","volume":"52","author":"LaPlante","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ijantimicag.2023.106836_bib0023","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106836_bib0024","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40262-020-00968-x","article-title":"Clinical pharmacokinetics of daptomycin","volume":"60","author":"Gregoire","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"9512","key":"10.1016\/j.ijantimicag.2023.106836_bib0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(06)68231-7","article-title":"Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus","volume":"367","author":"Diep","year":"2006","journal-title":"Lancet"},{"issue":"9320","key":"10.1016\/j.ijantimicag.2023.106836_bib0026","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(02)08713-5","article-title":"Genome and virulence determinants of high virulence community-acquired MRSA","volume":"359","author":"Baba","year":"2002","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ijantimicag.2023.106836_bib0027","first-page":"1076","article-title":"[Fatal pneumonia in an adolescent due to community-acquired methicillin-resistant Staphylococcus aureus positive for Panton-Valentine-leukocidin]","volume":"147","author":"van der Flier","year":"2003","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106836_bib0028","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1128\/IAI.00616-09","article-title":"Relevant role of fibronectin-binding proteins in Staphylococcus aureus biofilm-associated foreign-body infections","volume":"77","author":"Vergara-Irigaray","year":"2009","journal-title":"Infect Immun"},{"issue":"9092","key":"10.1016\/j.ijantimicag.2023.106836_bib0029","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(97)07324-8","article-title":"Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin","volume":"350","author":"Hiramatsu","year":"1997","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106836_bib0030","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00097-16","article-title":"Single- and repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil","volume":"60","author":"Matzneller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106836_bib0031","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.50.4.1376-1383.2006","article-title":"Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106836_bib0032","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/AAC.01386-12","article-title":"Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection","volume":"57","author":"MacGowan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106836_bib0033","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1128\/AAC.02308-12","article-title":"Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic\/pharmacodynamic model: exploring the \"seesaw effect\"","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:27:58Z","timestamp":1778549278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0924857923001152"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106836","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106836"}}